Does prior antidepressant treatment of major depression impact brain function during current treatment?

European Neuropsychopharmacology

Volumn 22, Issue 10, 2012, Pages 711-720

  Hunter, Aimee M ^a,b   Cook, Ian A ^a,b   Leuchter, Andrew F ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antidepressants; Classical conditioning; Electroencephalography; Pharmacological biomarkers; Placebo effect; Prefrontal cortex

Indexed keywords

FLUOXETINE; PLACEBO; VENLAFAXINE;

ADULT; ANTIDEPRESSANT ACTIVITY; ARTICLE; BRAIN FUNCTION; CONTROLLED STUDY; ELECTROENCEPHALOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; COHORT STUDIES; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; FLUOXETINE; HUMANS; LOS ANGELES; MALE; MIDDLE AGED; NEURONS; PREFRONTAL CORTEX; PSYCHIATRIC STATUS RATING SCALES; SELF REPORT; SINGLE-BLIND METHOD; THETA RHYTHM;

EID: 84865566495     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.02.005     Document Type: Article

References (56)

1. Ader R. The role of conditioning in pharmacotherapy. The Placebo Effect 1997, 138-165. Harvard University Press, Cambridge, MA; London. A. Harrington (Ed.).
2. Ader R., Cohen N. Behaviorally conditioned immunosuppression. Psychosom. Med. 1975, 37:333-340.
3. Allen J.J., Urry H.L., Hitt S.K., Coan J.A. The stability of resting frontal electroencephalographic asymmetry in depression. Psychophysiology 2004, 41(2):269-280.
4. Amsterdam J.D., Shults J. MAOI efficacy and safety in advanced stage treatment-resistant depression-a retrospective study. J. Affect. Disord. 2005, 89:183-188.
5. Amsterdam J.D., Maislin G., Potter L. Fluoxetine efficacy in treatment resistant depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 1994, 18:243-261.
6. Amsterdam J.D., Williams D., Michelson D., Adler L.A., Dunner D.L., Nierenberg A.A., et al. Tachyphylaxis after repeated antidepressant drug exposure in patients with recurrent major depressive disorder. Neuropsychobiology 2009, 59:227-233.
7. Asada H., Fukuda Y., Tsunoda S., Yamaguchi M., Tonoike M. Frontal midline theta rhythms reflect alternative activation of prefrontal cortex and anterior cingulate cortex in humans. Neurosci. Lett. 1999, 274(1):29-32.
8. Bares M., Brunovsky M., Kopecek M., Novak T., Stopkova P., Kozeny J., Sos P., Krajca V., Höschl C. Early reduction in prefrontal theta QEEG cordance value predicts response to venlafaxine treatment in patients with resistant depressive disorder. Eur. Psychiatry 2008, 23:350-355.
9. Bares M., Brunovsky M., Novak T., Kopecek M., Stopkova P., Sos P., Krajca V., Höschl C. The change of prefrontal QEEG theta cordance as a predictor of response to bupropion treatment in patients who had failed to respond to previous antidepressant treatments. Eur. Neuropsychopharmacol. 2010, 20:459-466.
10. Benedetti F., Pollo A., Lopiano L., Lanotte M., Vighetti S., Rainero I. Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses. J. Neurosci. 2003, 23:4315-4323.
11. Benedetti F., Carlino E., Pollo A. How placebos change the patient's brain. Neuropsychopharmacology 2011, 36:339-354.
12. Bhagwagar Z., Rabiner E.A., Sargent P.A., Grasby P.M., Cowen P.J. Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635. Mol. Psychiatry 2004, 9:386-392.
13. Brown W.A., Johnson M.F., Chen M.G. Clinical features of depressed patients who do and do not improve with placebo. Psychiatry Res. 1992, 41:203-214.
14. Bruder G.E., Sedoruk J.P., Stewart J.W., McGrath P.J., Quitkin F.M., Tenke C.E. Electroencephalographic alpha measures predict therapeutic response to a selective serotonin reuptake inhibitor antidepressant: pre- and post-treatment findings. Biol. Psychiatry 2008, 63(12):1171-1177.
15. Cook I.A., O'Hara R., Uijtdehaage S.H., Mandelkern M., Leuchter A.F. Assessing the accuracy of topographic EEG mapping for determining local brain function. Electroencephalogr. Clin. Neurophysiol. 1998, 107:408-414.
16. Cook I.A., Leuchter A.F., Morgan M., Witte E., Stubbeman W.F., Abrams M. Early changes in prefrontal activity characterize clinical responders to antidepressants. Neuropsychopharmacology 2002, 27:120-131.
17. Cook I.A., Leuchter A.F., Morgan M., Witte E., Stubbeman W.F., Siegman B., Abrams M. Changes in prefrontal activity characterize clinical response in SSRI nonresponders: a pilot study. J. Psychiatr. Res. 2005, 39:461-466.
18. Eikelboom R., Stewart J. Conditioning of drug-induced physiological responses. Psychol. Rev. 1982, 89:507-528.
19. Enck P., Benedetti F., Schedlowski M. New insights into the placebo and nocebo responses. Neuron 2008, 59:195-206.
20. Fava G.A. Can long-term treatment with antidepressant drugs worsen the course of depression?. J. Clin. Psychiatry 2003, 64:123-133.
21. Fava M., Rush A.J., Wisniewski S.R., Nierenberg A.A., Alpert J.E., McGrath P.J., et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am. J. Psychiatry 2006, 163:1161-1172.
22. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-I/P, Version 2.0) 1996, Biometrics Research Department, New York State Psychiatric Institute, New York.
23. Flaten M.A. Drug effects: agonistic and antagonistic processes. Scand. J. Psychol. 2009, 50:652-659.
24. Flaten M.A., Simonsen T., Waterloo K., Olsen H. Pharmacological classical conditioning in humans. Hum. Psychopharmacol. 1997, 12:369-377.
25. Goebel M.U., Trebst A.E., Steiner J., Xie Y.F., Exton M.S., Frede S., et al. Behavioral conditioning of immunosuppression is possible in humans. FASEB J. 2002, 16:1869-1873.
26. Hagemann D., Hewig J., Seifert J., Naumann E., Bartussek D. The latent state-trait structure of resting EEG asymmetry: replication and extension. Psychophysiology 2005, 42(6):740-752.
27. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960, 23:56-62.
28. Hunter A.M., Leuchter A.F., Morgan M.L., Cook I.A. Changes in brain function (QEEG cordance) during placebo lead-in and treatment outcomes in clinical trials for major depression. Am. J. Psychiatry 2006, 163:1426-1432.
29. Hunter A.M., Cook I.A., Leuchter A.F. Impact of antidepressant treatment history on clinical outcomes in placebo and medication treatment of major depression. Journal of clinical psychopharmacology 2010, 30:748-751.
30. Ishii R., Shinosaki K., Ukai S., Inouye T., Ishihara T., Yoshimine T., Hirabuki N., Asada H., Kihara T., Robinson S.E., Takeda M. Medial prefrontal cortex generates frontal midline theta rhythm. Neuroreport 1999, 10(4):675-679.
31. Konarski J.Z., McIntyre R.S., Soczynska J.K., Kennedy S.H. Neuroimaging approaches in mood disorders: technique and clinical implications. Ann. Clin. Psychiatry 2007, 19:265-277.
32. Leuchter A.F., Uijtdehaage S.H., Cook I.A., O'Hara R., Mandelkern M. Relationship between brain electrical activity and cortical perfusion in normal subjects. Psychiatry Res. 1999, 90:125-140.
33. Leuchter A.F., Cook I.A., Witte E.A., Morgan M., Abrams M. Changes in brain function of depressed subjects during treatment with placebo. Am. J. Psychiatry 2002, 159:122-129.
34. Leuchter A.F., Cook I.A., DeBrota D.J., Hunter A.M., Potter W.Z., McGrouther C.C., et al. Changes in brain function during administration of venlafaxine or placebo to normal subjects. Clin. EEG Neurosci. 2008, 175-181.
35. Leuchter A.F., Cook I.A., Hunter A.M., Korb A.S. A new paradigm for the prediction of antidepressant treatment response. Dialogues Clin. Neurosci. 2009, 11:435-446.
36. Leykin Y., Amsterdam J.D., DeRubeis R.J., Gallop R., Shelton R.C., Hollon S.D. Progressive resistance to a selective serotonin reuptake inhibitor but not to cognitive therapy in the treatment of major depression. J. Consult. Clin. Psychol. 2007, 75:267-276.
37. Longo D.L., Duffey P.L., Kopp W.C., Heyes M.P., Alvord W.G., Sharfman W.H., et al. Conditioned immune response to interferon-gamma in humans. Clin. Immunol. 1999, 90:173-181.
38. McGrath P.J., Stewart J.W., Fava M., Trivedi M.H., Wisniewski S.R., Nierenberg A.A., et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am. J. Psychiatry 2006, 163:1531-1541.
39. Nierenberg A.A., Fava M., Trivedi M.H., Wisniewski S.R., Thase M.E., McGrath P.J., et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am. J. Psychiatry 2006, 163:1519-1530.
40. Parsey R.V., Oquendo M.A., Ogden R.T., Olvet D.M., Simpson N., Huang Y.Y., Van Heertum R.L., Arango V., Mann J.J. Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study. Biol. Psychiatry 2006, 59:106-113.
41. Posternak M.A., Zimmerman M. Dual reuptake inhibitors incur lower rates of tachyphylaxis than selective serotonin reuptake inhibitors: a retrospective study. J. Clin. Psychiatry 2005, 66:705-707.
42. Price D.D., Finniss D.G., Benedetti F. A comprehensive review of the placebo effect: recent advances and current thought. Annu. Rev. Psychol. 2008, 59:565-590.
43. Rush A.J., Trivedi M.H., Wisniewski S.R., Nierenberg A.A., Stewart J.W., Warden D., et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 2006, 163:1905-1917.
44. Sargent P.A., Kjaer K.H., Bench C.J., Rabiner E.A., Messa C., Meyer J., Gunn R.N., Grasby P.M., Cowen P.J. Brain serotonin 1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch. Gen. Psychiatry 2000, 57:174-180.
45. Savitz J.B., Drevets W.C. Imaging phenotypes of major depressive disorder: genetic correlates. Neuroscience 2009, 164:300-330.
46. Sharma V. Loss of response to antidepressants and subsequent refractoriness: diagnostic issues in a retrospective case series. J. Affect. Disord. 2001, 64:99-106.
47. Siegel S. Opioid expectation modifies opioid effects. Fed. Proc. 1982, 41:2339-2343.
48. Smit D.J., Posthuma D., Boomsma D.I., Geus E.J. Heritability of background EEG across the power spectrum. Psychophysiology 2005, 42(6):691-697.
49. Solomon D.A., Leon A.C., Mueller T.I., Coryell W., Teres J.J., Posternak M.A., Judd L.L., Endicott J., Keller M.B. Tachyphylaxis in unipolar major depressive disorder. J. Clin. Psychiatry 2005, 66:283-290.
50. Stewart J., Badiani A. Tolerance and sensitization to the behavioral effects of drugs. Behav. Pharmacol. 1993, 4:289-312.
51. Stewart J.L., Coan J.A., Towers D.N., et al. Frontal EEG asymmetry during emotional challenge differentiates individuals with and without lifetime major depressive disorder. J. Affect. Disord. 2011, 129(1-3):167-174.
52. Stockhorst U., Gritzmann E., Klopp K., Schottenfeld-Naor Y., Hübinger A., Berresheim H.W., Steingrüber H.J., Gries F.A. Classical conditioning of insulin effects in healthy humans. Psychosom. Med. 1999, 61:424-435.
53. Tarpy R.M. Contemporary Learning Theory and Research 1997, McGraw-Hill, New York.
54. Tenke C.E., Kayser J., Manna C.G., et al. Current source density measures of electroencephalographic alpha predict antidepressant treatment response. Biol. Psychiatry 2011, 70(4):388-394.
55. Thase M.E. Preventing relapse and recurrence of depression: a brief review of therapeutic options. CNS Spectr. 2006, 11(12 Suppl 15):12-21.
56. Thase M.E., Rush A.J. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J. Clin. Psychiatry 1997, 58:23-29.